Agilent Technologies Inc. (NYSE: A) and Baylor College of Medicine, both
known for their expertise in metabolomics, are working together to
advance research and training in this vital branch of the life sciences.
Agilent Technologies Inc. (NYSE: A) today introduced the GenetiSure
Pre-Screen Kit , a high-throughput oligonucleotide microarray for
screening aneuploidy and other genomic aberrations in the 5- to 10-Mb
range from single cells in three- and five-day embryos.
Dako, an Agilent Technologies company and a worldwide provider of
cancer diagnostics, and Cell Signaling Technology (CST), a worldwide
provider of antibodies, today announced that they have entered into a
strategic partnership to supply antibodies for use in Dako-branded
companion diagnostics products.
Agilent Technologies Inc. (NYSE: A) today announced that the China Food
and Drug Administration has approved the company’s SureScan Dx
microarray scanner as a medical device for in vitro diagnostic
Sign-up for Dako, an Agilent Technologies company, and ONO PHARMACEUTICAL CO., LTD. announce collaboration on development of PD-L1 companion diagnostic test for investigational cancer drug Opdivo(R) (nivolumab) investment picks
Agilent Technologies Inc. (NYSE:A) today launched two new products—the
HaloPlex HS target enrichment system and ClearSeq
Comprehensive Cancer research panel—designed to improve the speed and
accuracy of clinical cancer research.
Agilent Technologies Inc. (NYSE:A) today announced the following
webcasts for the investment community:
Barclays Global Healthcare Conference Wednesday,
March 11, 2015, at 10:15 a.m. (ET) Loews Miami Beach Hotel, Miami,
Florida Mark Doak, senior vice president, Agilent CrossLab Group
Agilent Technologies Annual Meeting of Shareholders Wednesday,
March 18, 2015, at 8:00 a.m. (PT) Agilent headquarters, Santa
Clara, California Agilent executive team
Links to the webcasts will be available at www.investor.agilent.com .
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.